ArticleFrontiers in public health2025
Perception of phage therapy and research across selected professional and social groups in Poland.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Genetic engineering of cyanophages for harmful cyanobacterial bloom treatment-A mini review.Synthetic and systems biotechnology · 2027Review
- Performance of large language models as a source of clinical information on bacteriophage therapy.Npj viruses · 2026Article
- Bacteriophages as Potential Sustainable Alternatives to Antibiotics for ControllingAntibiotics (Basel, Switzerland) · 2026Review
- Expanding the Antimicrobial Toolbox with Therapeutic Viruses: Mechanisms, Pharmaceutical Formulation, and Translational Outlook.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Exploration of Providers' Perceptions and Attitudes Toward Phage Therapy and Intentions for Future Adoption as an Alternative to Traditional Antibiotics in the US-A Cross-Sectional Study.International journal of environmental research and public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is no doubt that in the last 15 years phage therapy has re-emerged from the shadow of antibiotics, from the perspective of both scientists and various patient advocacy groups. Despite some important progress, there is little to no data on phage therapy perceptions in key groups, i.e., patients and their relatives, physicians and anyone who could potentially become infected with antibiotic-resistant bacteria. To the best of our knowledge, with 1,098 collected questionnaires, this article constitutes the first large-scale analysis on phage therapy perceptions, interest and knowledge among ordinary people in a country with a long, internationally recognized, tradition of treating patients with phages. In addition to 36 general questions addressed to everyone (including lay people), representatives of the health care sector and science and research sector received individually selected questions. Further, each participant had a chance to take part in a short quiz (consisting of 12 questions) verifying their basic knowledge about bacteriophages, their history, biology and therapeutic connotations. Awareness of antibiotic resistance was very high (above 90%) but contradicted the low level of knowledge about associated risks (12%). Consciousness of phage therapy varied between 8.9% (people taking care of household chores as their primary activity) to 37.7% (people with higher education) and 39.7% (inhabitants of large cities) while the readiness to use such treatments was very high (84.4%) despite the need to pay for it. The level of awareness of bacteriophages and phage therapy was clearly correlated with the acceptance of this type of treatment and the social acceptance to allocate further funds for the development of phage research. Interestingly, physicians were quite reluctant to deepen their knowledge in the field of phage therapy with just over one third (37.5%) ready to do so. With the COVID-19 pandemic in the background, we also explored how the pandemic influenced the interest in experimental therapies in general, which makes this article a potential universal compendium on perceptions of experimental therapies in the coming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.